The only “Innovation center for the production of vaccines” in Central Asia will be opened in the Tashkent region of Uzbekistan. As reports asiaplustj.info, the corresponding memorandum, within the framework of the SCO summit in Samarkand, was signed by the Ministry of Innovative Development of Uzbekistan and Luye Investment Group Co., Ltd. The construction of the center, worth 100 million USD, is scheduled for 2023-2028.
It is noted that the “Innovative center for the production of vaccines” will become the only full-cycle biotechnological enterprise in Central Asia, which will permit delivering high-tech products to the local market and the market of the CIS countries. The center will produce 200 million doses of 10 types of vaccines against various viruses, including hepatitis A, hepatitis B, papillomavirus, measles, tetanus and other diseases, worth 2 billion USD a year.
